Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and ...

A little less than a year after targeting Moderna in an mRNA vaccine patent lawsuit, GSK is widening the scope of its litigation by throwing its rival’s next-generation COVID-19 shot into the fold. In ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...

Moderna has opened the doors to its long-anticipated Harwell vaccine production facility in the U.K., reaffirming its commitment to Britain as its competitors take shots at the country and retreat ...

Investors may be asking whether Moderna's current share price reflects its underlying worth, or if the market is mispricing ...

Moderna, Inc. (NASDAQ:MRNA) is one of the noteworthy S&P 500 stocks Jim Cramer highlighted. Cramer highlighted that the company is likely to remain unprofitable for “years to come,” as he stated: Next ...

Could this player be heading into a new era of growth?

Moderna (NASDAQ:MRNA) has agreed to resolve a patent litigation in which Alnylam Pharmaceuticals (NASDAQ:ALNY) has alleged that the delivery technology used in the company’s COVID-19 vaccine has ...

Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe." Hughes’ comments came as the company opened a 150 ...

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% ...